Last $1.25 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

rbc life sciences inc (RBCL) Snapshot

Open
$1.25
Previous Close
$1.25
Day High
$1.25
Day Low
$1.25
52 Week High
09/18/14 - $1.85
52 Week Low
05/8/14 - $0.46
Market Cap
2.8M
Average Volume 10 Days
55.0
EPS TTM
$-0.32
Shares Outstanding
2.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RBC LIFE SCIENCES INC (RBCL)

Related News

No related news articles were found.

rbc life sciences inc (RBCL) Related Businessweek News

No Related Businessweek News Found

rbc life sciences inc (RBCL) Details

RBC Life Sciences, Inc., through its subsidiaries, develops, manufactures, markets, and distributes nutritional supplements, and personal care and medical products in the United States, Canada, Taiwan, Hong Kong, and Malaysia. Its Nutritional Products segment distributes nutritional supplements and personal care products, including herbs, vitamins, and minerals, as well as natural skin, hair, and body care products under the RBC Life brand. This segment’s products include Stem-Kine, a dietary supplement; Microhydrin and Microhydrin Plus antioxidants; NeuroBright to support brain function, and enhance energy and acuity; Organic spirulina that provides nutrients and proteins; OliViva to support the immune system and cardiovascular system; Colo-Vada Plus, a cleansing program; HydraCel to enhance the quality of drinking water; 24 Seven, a multivitamin/mineral supplement; Immune 360 to nourish and support the function of the immune system; and VitAloe, a blend of research-backed ingredients. This segment sells its products through a network of independent distributors and licensees. The company’s Medical Products segment markets wound care products under the MPM Medical brand, including cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials, and Lidocaine hydrogel for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. It also offers other wound care products to reduce destruction to skin and tissue caused by radiation; and to reduce pain and itching in the skin, and the internal mucosa caused by radiation reactions or reactions to certain cancer medications. This segment sells its products to hospitals, nursing homes, home health care agencies, clinics, and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors. The company was founded in 1988 and is headquartered in Irving, Texas.

76 Employees
Last Reported Date: 03/27/14
Founded in 1988

rbc life sciences inc (RBCL) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $325.0K
President and Director
Total Annual Compensation: $280.0K
Compensation as of Fiscal Year 2013.

rbc life sciences inc (RBCL) Key Developments

RBC Life Sciences Inc. Announces Executive Changes

Effective September 26, 2014, Mr. Kevin B. Young resigned his position as Vice President - Sales of RBC Life Sciences Inc. to participate in the Company's network marketing distribution system as an independent Associate. Mr. Young's duties will be assumed by Mr. Barton R. Dangerfield, Vice President - Marketing, until a replacement for Mr. Young is found. On September 26, 2014, the Board of Directors of the company appointed Ms. Daley L. Seeker, to serve as the company's Vice president - Finance, Chief Financial Officer, Treasurer and Secretary effective October 6, 2014. Ms. Seeker will join the Company on October 6, 2014 having held various positions, most recently as an Assurance Supervisor, in the Assurance Practice of McGladrey LLP, from 2011 to present. From 2010 until 2011, Ms. Seeker served as a Staff Auditor for the accounting firm of Gindler, Chappell, Morrison & Co., PC, and from 2008 to 2010, as an Audit Associate with McGladrey.

RBC Life Sciences Inc. Enters into Two-Year Exclusive Distributorship Agreement with Coral Club International, Inc

On August 22, 2014, RBC Life Sciences Inc. entered into a two-year exclusive distributorship agreement effective as of August 1, 2014 with Coral Club International, Inc. This Agreement replaces a ten-year exclusive distributorship agreement between the parties that automatically renewed for a one-year term following expiration of the initial term on July 1, 2014. CCI is the company's principal licensee and accounted for virtually all of the company's licensees' net sales in the six months ended June 30, 2014 and 2013, respectively. Pursuant to the Agreement, CCI's exclusive territory includes Russia and other countries located primarily in Europe and Central Asia, which represents an expansion of the territory set out in the Former Agreement. In consideration of the rights granted to CCI under the Agreement, CCI is required to purchase certain minimum amounts of products from the Company each year, which minimum amounts are consistent with the Former Agreement. Under the Former Agreement, CCI was required to pay the company a monthly royalty calculated as a percentage of its sales of the company's products. Under the Agreement, in lieu of a royalty, the prices at which products are sold to CCI were marked up as of the effective date of the Agreement to include the royalty so that no additional royalty will be due upon the sale of the company's products by CCI. To affect the transition of royalty calculations under the Former Agreement and the Agreement, the company will recognize on a one-time basis royalty revenue of approximately $476,000 in the third quarter of 2014.

RBC Life Sciences, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

RBC Life Sciences Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of $7.9 million, an 18% increase over net sales of $6.7 million in the second quarter of 2013. The company reported a net loss of $7,000, or $0.00 per basic and diluted share, compared to a net loss of $147,000, or $0.07 per basic and diluted share, for the same quarter last year. Earnings before income taxes were $9,000 compared to loss before income taxes of $226,000 a year ago. Operating income was $33,000 compared to operating loss of $198,000 a year ago. For the six months, net sales were $13.6 million, a 10% increase over net sales of $12.4 million in the same period last year. Net loss was $385,000, or $0.17 per basic and diluted share, compared to a net loss of $155,000, or $0.07 per basic and diluted share, in the comparable period in 2013. Loss before income taxes was $509,000 compared to $232,000 a year ago. Operating loss was $459,000 compared to operating loss of $174,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBCL:US $1.25 USD 0.00

RBCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RBCL.
View Industry Companies
 

Industry Analysis

RBCL

Industry Average

Valuation RBCL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 0.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RBC LIFE SCIENCES INC, please visit www.rbclifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.